Radical treatment for oligometastatic NSCLC

Fiona McDonald, MA, MBBS, MRCP, FRCR, MD, of the Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK, discusses oligometastatic non-small cell lung cancer (NSCLC), and whether radical treatment should be the standard of care for this disease. Dr McDonald highlights a recent update on a study (NCT01725165) that revealed exciting overall survival data in the synchronous oligometastatic setting, as well as the first randomized evidence to also suggest a survival benefit in the metachronous oligometastatic setting. Looking towards the future, she discusses the UK-based Stereotactic Ablative Radiotherapy for Oligometastatic NSCLC (SARON; NCT02417662) and Conventional Care Versus Radioablation for Extracranial Oligometastases (CORE; NCT02759783) studies. Lastly, oligoprogressive disease is discussed; including the HALT study (ISRCTN53398136). This interview took place at the British Thoracic Oncology Group (BTOG) 2019 Annual Conference in Dublin, Ireland.